IntroductIon
Autoimmune polyendocrine syndrome-1 (APS-1) is an autoimmune autosomal-recessive condition causing parathyroid and adrenal insufficiency, alopecia, chronic mucocutaneous candidiasis, ectodermal dystrophy and, rarely, hepatitis. This condition is also known as autoimmune polyendocrinopathy candidiasisectodermal dystrophy (APECED), Whitaker's syndrome or Blizzard's syndrome. The syndrome was first described by Neufeld and Blizzard 1 in the 1960s as a rare syndrome presenting in childhood. We describe an unusual and aggressive autoimmune hepatitis, a rare presentation of APS-1 syndrome in a young woman, causing hyperacute fulminant hepatic failure (FHF), i.e. liver disease that causes encephalopathy within 8 weeks of onset of symptoms or within 2 weeks of onset of jaundice in a patient without prior evidence of liver disease. 2 This case highlights the importance of a multi-system approach to acute liver failure and illustrates the contribution of aggressive medical management in avoiding the need for liver transplantation. 3 
cASE rEPort
A 23-year-old woman presented to a local hospital with a 4-day history of worsening jaundice. She was transferred to the tertiary liver unit in Edinburgh with FHF. At the time of transfer, the patient had developed grade II encephalopathy with agitation and restlessness with a Glasgow Coma Scale of 10 (E3V4M5). There was no history of a preceding intercurrent illness, nor had any new hepatotoxic medications been commenced. Collateral history confirmed episodic alcohol consumption on weekends, amounting to less than 3 units per day, and no paracetamol, over-the-counter drug or herbal medication use.
She had previously been diagnosed with APS-1, (Addison's disease, hypoparathyroidism, alopecia and pernicious anaemia) at the age of four. She had been admitted several times for refractory hypocalcaemia resulting in tetany, despite the use of high dose calcium and vitamin D supplements. She had recently started taking a recombinant parathyroid hormone analogue (teriparatide) for resistant hypoparathyroidism. At presentation the patient was taking the following medications: calcitriol 2 mcg once daily, teriparatide (recombinant parathyroid hormone analogue) 20 mcg once daily, two Adcal D3 tablets (3000 mg calcium + 800 iU cholecalciferol) daily, fludrocortisone 250 mcg daily, hydrocortisone 30 mg daily in divided dose, Slow-K 1800 mg daily in divided doses and magnesium glycerophosphate 8 mmol daily in divided doses. Her endocrine replacement therapies were regularly monitored by the local endocrinology team. There was no concern regarding adherence as Fulminant hepatic failure in autoimmune polyendocrine syndrome type-1 ABStrAct Fulminant hepatic failure is liver disease that causes encephalopathy within 8 weeks of onset of symptoms or within 2 weeks of onset of jaundice in a patient without prior evidence of liver disease. Autoimmune polyendocrine syndrome type-1 is an autoimmune autosomal-recessive condition causing parathyroid and adrenal insufficiency, alopecia, chronic mucocutaneous candidiasis, ectodermal dystrophy and, rarely, hepatitis. Although the liver can be affected as a consequence of the autoimmune process, the spectrum of disease activity is varied. Autoimmune hepatitis develops in 10-20% of patients and successful liver transplantation has been reported in pediatric patients who failed immunosuppressive treatment. We report fulminant hepatic failure in an adult patient with autoimmune polyendocrine syndrome type-1 who responded to medical treatment and did not require liver transplantation. We highlight the diagnostic scoring system for autoimmune hepatitis and the referral criteria for liver transplantation in fulminant hepatic failure. Case of the Quarter 1 R Sinha, 2 AR Chapman, 3 GT Reid, 4 PC Hayes this condition was diagnosed at an early age and episodes of accidental missed doses resulted in symptoms such as tetany requiring hospital admission. There was no family history of liver disease. She had no known liver disease and her previous liver biochemistry was unremarkable. She was the younger of two children of non-consanguineous parents.
On examination, the patient was jaundiced and encephalopathic with asterixis. She had marked alopecia but there were no stigmata of chronic liver disease. Abdominal examination was unremarkable with no evidence of ascites. There was no enamel hypoplasia or nail dystrophy. She had FHF and, as per King's College Hospital criteria (Table 1) , she fulfilled two criteria in category 6 (encephalopathy and bilirubin >300 μmol/l). Initial investigation results are shown in Table 2 . Her pre-treatment aggregate score on the International Autoimmune Hepatitis scoring system 4 ( Table 3 ) was 18.
In view of the syndrome and its association of mucocutaneous candidiasis -in the context of elevated white cell and differentials -a gastroscopy was performed which showed some evidence of reflux oesophagitis but no candidiasis. Although there was no evidence of mucocutaneous fungal infection, she received prophylactic anti-fungals as part of the FHF management protocol. Computed tomography of the brain found no intracranial causes of reduced conscious level and computed tomography of the abdomen found no evidence of disseminated malignancy. The patient required intubation to facilitate transjugular biopsy of the liver, with histology shown in Figure 1 .
HIStology
Histological examination of a liver biopsy specimen ( Figure 1 ) showed significant fibrosis and widespread destruction of hepatic parenchyma, approximately 40% by area. There were areas of collapse and hepatocyte loss, and in areas of surviving parenchyma there were numerous lymphocytes present and occasional plasma cells. No eosinophils were noted. Appearances were therefore suggestive of immunologically mediated, widespread destruction of liver parenchyma, consistent with acute autoimmune hepatitis. Having not fully met the criteria for transplantation, she was not listed for urgent liver transplantation and was instead treated with pulsed methylprednisolone (based on body weight) given the strong suspicion of autoimmune hepatitis shown by the liver biopsy.
She remained intubated because of encephalopathy and continued to be managed in the ITU. Liver parameters were very slow to resolve and she was Fulminant hepatic failure extubated on day 11. Subsequently she was switched to intravenous hydrocortisone followed by oral prednisolone upon restoration of consciousness.
During her post intensive care recovery, she had profound bilateral leg weakness, right foot drop and significantly deranged electrolytes. She remained deeply jaundiced (bilirubin>300 μmol/L) but gradual improvements in alanine transaminase, prothrombin time and albumin were noted, with no evidence of encephalopathy.
On day 28 she had a percutaneous liver biopsy for persistent hyperbilirubinemia and fluctuation in transaminses, despite preserved synthetic function. The introduction of a second immunosuppressive agent was considered but not commenced pending results. The biopsy was reassuring (Figure 2) , with a reported disappearance of inflammatory activity, together with some collapse and necrosis in keeping 
dIScuSSIon
Fulminant hepatic failure or acute liver failure is characterised by hepatocellular necrosis resulting in impaired hepatic synthetic function in the absence of pre-existing liver disease. Based on the development of encephalopathy from the onset of jaundice, acute liver failure can be classified into the O'Grady system of hyper-acute (less than 7 days), acute (1-4 weeks) and sub-acute (4-12weeks), or the Bernau system of fulminant (0-2weeks) or sub-fulminant (2-12weeks).
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Survival is as low as 15% 6 without liver transplantation and is inversely related to the interval between jaundice to onset of encephalopathy. The most common cause of acute liver failure is paracetamol toxicity, followed by viral hepatitis.
It is important to establish the cause of FHF in order to initiate appropriate treatment, to prognosticate and to guide consideration of liver transplantation. A liver screen comprising of a panel of blood investigation for viral hepatitis (A, B, C, D, E, CMV, EBV and HIV), autoantibodies, serum immunoglobins, caeruloplasmin, alpha-1 antitrypsin, ferritin and alpha-fetoprotein forms part of the initial assessment for any acute liver injury presentation. A trans-abdominal ultrasound provides a further quick assessment in excluding focal hepatic lesions or underlying chronicity. Occasionally, computed tomography of the chest, abdomen and pelvis may be required if the suspicion of malignancy is high in order to search for liver infiltration or focal malignancy elsewhere.
Severe autoimmune hepatitis causing FHF is rare. Diagnosis is based on excluding other causes, on the presence of gamma globulin levels > 20 g/L, significant titers of autoantibodies, and the presence of a marked lymphoplasmocytic infiltrate on a histological examination of liver biopsy specimens. 4 Autoimmune polyendocrine syndrome-1 is a rare autosomal-recessive condition associated with mutations of the AIRE (Autoimmune Regulator) gene on chromosome 21, 7 which is involved in central and peripheral immune tolerance mechanisms. Although rare, the prevalence is relatively higher in Iranian Jewish, Sardinian, Norwegian and Finnish populations. Mutations cause loss of central immune tolerance; failure to eliminate autoreactive T cells in the thymus, and their escape to the periphery. These patients are susceptible to mucocutaneous candidiasis and multiple endocrine and non-endocrine autoimmune diseases.
The diagnosis is classically based on the combination of any two of the following three major criteria: chronic mucocutaneous candidiasis, hypoparathyroidism, and autoimmune primary adrenocortical insufficiency (Addison's disease). The first endocrinopathy to manifest Fulminant hepatic failure is usually hypoparathyroidism followed by Addison's disease. 8 Other autoimmune processes that may co-exist in APS-1 are primary gonadal failure, autoimmune thyroid disease, type I diabetes mellitus, pernicious anaemia, intestinal dysfunction, autoimmune hepatitis of varying severity and alopecia. 9 To our knowledge this is the first presentation of acute FHF due to autoimmune hepatitis described in an adult with APS-1. The diagnosis of autoimmune hepatitis was confirmed on biopsy and with the use of the criteria of the International Autoimmune Hepatitis Group (Table  3) . 4 Only two orthotopic liver transplantations 2,10 have been described, both in paediatric patients for acute or chronic liver failure. Of these patients only one survived.
Our patient was managed with single agent immunosuppression in an intensive care setting, with clinical, biochemical and histological improvement noted over a 4-week period. Due to the low prevalence of this condition, detection of liver involvement may be delayed. If medical therapy is unsuccessful, liver transplantation remains an option. In conclusion, this young woman had a first presentation of FHF on a background of APS-1 without evidence of chronicity on liver biopsy and was successfully managed with immunosuppression and supportive therapy. Early recognition of acute liver failure using the King's College Hospital criteria and referral to a tertiary liver unit is key to the outcome. Furthermore, prognosis of FHF is also dependent on etiology, clinical presentation and course, biological status, gender and timing of liver transplantation. 
